Regeneron reports 73% response rate for ovarian cancer drug trial
Covered in this story
What has happened since
- Regeneron Pharmaceuticals is up 7.9% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Regeneron Pharmaceuticals
- Jefferies: $735 → $930 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.